Shots:
Novo Nordisk has reported P-III (REDEFINE 2) trial data assessing CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, QW, SC) vs PBO in 1,206 obese/overweight pts (~102Kg) and type 2 diabetes for 68wks., and followed flexible dosing protocol with 61.9% pts reaching highest dose after 68wks.
Trial met its co-1EPs demonstrated 15.7% superior weight loss…
Shots:
The P-Ib/IIa trial assessed amycretin (Q1W) vs PBO in overweight or obese patients (n=125) in 5 parts
Part A (single ascending dose) assessed PK & determined the initial dose for Part B (multiple dose arm), which evaluated safety/tolerability over 36wks. Parts C, D, & E (PoC) evaluated weight loss with 3 doses (1.25mg,…
Shots:
The P-IIIb (STEP UP) study assessed semaglutide (7.2mg) vs semaglutide (2.4mg) & PBO as an adjunct to lifestyle intervention in obese adults (n=1,407; BMI ≥30kg/m^2) without diabetes for 72wks. STEP program also includes STEP UP T2D study of semaglutide (7.2mg) in obese adults (n=512) with T2D for 72wks.
Study met its 1EP, depicting…
Statistics show that at least 129 million people in the United States have a chronic illness. To effectively deal with chronic illnesses, one needs a thorough approach that includes customized supplements and medication. The management of these prolonged conditions requires consistent attention to prevent complexities while ensuring better living standards for patients.
Continue reading to learn about…
Shots:
Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity
He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I study
The interview shows how…

